Patent · US Active

Chimeric antigen receptor (CAR) comprising a CD19-binding domain

US10457730B2 · kind B2 · utility

10Cited by

0References

24Claims

0Family size

Assignee

UCL BUSINESS PLC · GB

Inventors

Martin Pulé · London, GB
Leila Mekkaoui · London, GB
Persis Amrolia · London, GB
Sara Ghorashian · London, GB
Anne Kramer · Berlin, DE
Gordon Cheung · London, GB

Key dates

Filing date	Mar 4, 2016
Grant date	Oct 29, 2019
Priority date	—
Expiry date	Dec 3, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/15043
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.